Rivus to show animal data on muscle-sparing GLP-1

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

The preclinical results for RV-8451, an oral GLP-1 pill, will go on display as three posters at ObesityWeek in Washington, DC, in November.

If you sat down to write a wish list for a weight-loss drug, a pill that goes after fat and leaves muscle alone would probably land near the top. Rivus Pharmaceuticals says that’s what it has been building, and it has now announced where and when the early evidence will be shown [1].

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3717

Rivus Pharmaceuticals

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to advancing cardiometabolic health through the development of oral small-molecule therapeutics. The company specializes in controlled metabolic accelerators (CMAs), a novel class of medicines that leverage mitochondrial uncoupling to increase energy expenditure and promote fat-specific weight loss while preserving lean muscle mass. Rivus targets obesity and associated cardiometabolic diseases including metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), and type 2 diabetes, with its lead candidate HU6 advancing through Phase 2 clinical trials. The company's approach addresses fundamental metabolic dysfunction by targeting mitochondrial biology, positioning it to address multiple age-related cardiometabolic conditions through a single therapeutic mechanism.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE